Author

J. R. Pritchard

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cancer Biology· 1 Evolutionary Biology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

B. Zhao· 2 shared H. Inam· 2 shared A. Shah· 1 shared B. Landry· 1 shared C. Dong· 1 shared C. Liu· 1 shared D. M. McCandlish· 1 shared E. O'Brien· 1 shared

Activity by Year

2019-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersEvolutionary Biology

B. Zhao

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Agent-based models help interpret patterns of clinical drug resistance by contextualizing competition between distinct drug failure modes.

S. M. Leighow, B. Landry, M. J. Lee, S. R. Peyton, J. R. Pritchard

The paper uses agent-based models to show that microenvironmental resistance can compete with genetic resistance in tumors, explaining observed diversity in drug failure modes.

bioRxiv · Feb 25, 2022Bioengineering

Genomic and experimental evidence that alternate transcription initiation of the Anaplastic Lymphoma Kinase (ALK) kinase domain does not predict single agent sensitivity to ALK inhibitors.

H. Inam, I. Sokirniy, Y. Rao, A. Shah, F. Naeemikia, E. O'Brien, C. Dong, D. M. McCandlish, J. R. Pritchard

The paper reanalyzes ALKATI's role in melanoma using genomic and experimental methods, finding it does not predict single-agent ALK inhibitor sensitivity.

bioRxiv · Jun 17, 2021 · PreprintBioengineering

Refined quantification of infection bottlenecks and pathogen dissemination with STAMPR

K. Hullahalli, J. R. Pritchard, M. K. Waldor

This paper introduces STAMPR, a method to improve the accuracy of measuring infection bottlenecks and pathogen dissemination using barcoded bacterial data.

bioRxiv · Apr 28, 2021Microbiology

Multi-scale predictions of drug resistance epidemiology suggest a new design principle for rational drug design.

S. Leighow, C. Liu, H. Inam, B. Zhao, J. R. Pritchard

This paper identifies a new principle in drug resistance where the most likely mutations, not the most resistant ones, dominate clinical outcomes, suggesting a strategy to minimize resistance through drug design.

bioRxiv · Sep 19, 2019 · PreprintEvolutionary Biology

Evolution of the nonsense-mediated decay (NMD) pathway is associated with decreased cytolytic immune infiltration

J. R. Pritchard, B. Zhao

The paper examines how NMD pathway evolution affects immune cytolytic activity and patient survival in tumors using TCGA datasets and machine learning.

bioRxiv · Feb 4, 2019 · PreprintCancer Biology